Bao Le

Consigliere Generale presso SENSEI BIOTHERAPEUTICS, INC.

Health Technology

Profilo

Bao Le is currently the Vice President of Regulatory Affairs at Sensei Biotherapeutics, Inc. She started this job in 2021.
Previously, she worked as the Vice President and Head of Global Regulatory Affairs at enGene, Inc.

Posizioni attive di Bao Le

Società	Posizione	Inizio
SENSEI BIOTHERAPEUTICS, INC.	Consigliere Generale	01/06/2021

Tutte le posizioni attive di Bao Le

Precedenti posizioni note di Bao Le

Società	Posizione	Fine
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	Consigliere Generale	-

Vedi nel dettaglio l'esperienza di Bao Le

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Bao Le

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
SENSEI BIOTHERAPEUTICS, INC.	Health Technology

Aziende private	1
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	Health Technology